Automate Your Wheel Strategy on MLTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MLTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLTX
- Rev/Share 0.0016
- Book/Share 5.6563
- PB 9.5962
- Debt/Equity 0.2142
- CurrentRatio 16.6471
- ROIC -0.4611
- MktCap 3406215096.0
- FreeCF/Share -2.6352
- PFCF -20.4257
- PE -19.2357
- Debt/Assets 0.1647
- DivYield 0
- ROE -0.4161
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MLTX | Rothschild & Co Redburn | -- | Neutral | -- | $65 | July 28, 2025 |
| Upgrade | MLTX | Wolfe Research | Peer Perform | Outperform | -- | $61 | May 19, 2025 |
| Initiation | MLTX | RBC Capital Mkts | -- | Outperform | -- | $67 | March 18, 2025 |
| Upgrade | MLTX | Goldman | Neutral | Buy | $62 | $82 | Jan. 17, 2025 |
| Downgrade | MLTX | Wolfe Research | Outperform | Peer Perform | -- | -- | Aug. 26, 2024 |
News
2 Logical Mid-Cap Biotech Buyout Targets
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on their own, but would make logical buyout candidates: Abivax Société Anonyme and MoonLake Immunotherapeutics. Both have late-stage assets targeting large markets, and both companies should file for their first FDA approvals in 2026.
Read More
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
Published: August 27, 2025 by: The Motley Fool
Sentiment: Positive
For decades, savvy investors have been finding stocks that can produce dramatic gains in relatively short timeframes by sifting through the biotechnology universe. In this wonky industry, positive clinical trial results can cause small-cap stocks to double in value in a single trading session.
Read More
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
Read More
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights significant buyout potential of company and validates its late-stage pipeline value.
Read More
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Read More
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Read More
About MoonLake Immunotherapeutics (MLTX)
- IPO Date 2020-10-20
- Website https://www.moonlaketx.com
- Industry Biotechnology
- CEO Jorge Santos da Silva
- Employees 100